ProQR Therapeutics N.V.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel Anton de Boer
- Full Time Employees
- 166
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Zernikedreef 9 Leiden Netherlands 2333 Ck
- IPO Date
- Sep 18, 2014
- CIK
- 0001612940
- Website
- proqr.com
- Similar Companies
- Business
- ProQR Therapeutics N.V. (Nasdaq: PRQR) is a clinical-stage biotechnology company that discovers, develops and advances RNA therapies based on its proprietary Axiomer RNA editing platform technology, which leverages ADAR-mediated editing to correct single nucleotide mutations or modulate protein expression in RNA for rare and prevalent diseases with high unmet need. Founded in 2012 and headquartered in Leiden, the Netherlands, with operations extending to Cambridge, Massachusetts, the company targets disorders originating primarily in the liver and nervous system through programs deliverable to hepatocytes; its main products in the pipeline include AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP), AX-1412 for cardiovascular diseases targeting Beta-1,4-galactosyltransferase 1 (B4GALT1), AX-2402 for Rett syndrome, AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3), AX-0601 for obesity and Type 2 diabetes, AX-1005 for undisclosed cardiovascular disease targets, AX-9115 for a rare metabolic condition, and additional early-stage efforts in central nervous system disorders and other unnamed targets. ProQR maintains strategic collaborations including a global licensing and research partnership with Eli Lilly and Company since 2021—expanded in December 2022 from five to ten targets with an option for fifteen, yielding increased revenue from new projects in 2024—a September 2024 partnership with Théa Open Innovation to further develop sepofarsen and ultevursen for rare genetic eye diseases, and an expanded $9.1 million funding agreement with the Rett Syndrome Research Trust announced in December 2024 to accelerate AX-2402 toward clinical trials, alongside anticipated mid-2025 updates on GalNAc delivery optimization and potential milestone income from existing alliances.
ProQR Announces First Quarter 2026 Operating and Financial Results
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR Announces Year End 2025 Operating and Financial Results
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
ProQR Announces Planned Changes to Board Composition
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Brokerages
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
ProQR to Participate in 8th Annual Evercore Healthcare Conference
ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates